NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-145-2019-0-US-01 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF US 62/947,135 Abandoned
NCI E-149-2015-0-US-06 METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD US DIV 16/710,287 11629334 Issued PDF
NCI E-003-2020-0-US-01 A Vaccine Consisting Of Whole Tumor Cells (WTC) Integrated With Amphiphilic Immunogenic Components (AIC) Enhances Antitumor immunity And Augments Tumor Infiltrating Lymphocytes For Adoptive Transfer Therapies. US 62/946,934 Abandoned
NIBIB E-013-2020-0-US-01 BRIDGED HOLLOW ORGANOSILICA NANOCAPSULES, PRECURSORS, AND USES THEREOF US 62/946,511 Abandoned
NIAID E-153-2019-0-US-01 MUMPS AND MEASLES VIRUS IMMUNOGENS AND THEIR USE US 62/946,902 Abandoned
NHLBI E-134-2017-3-SG-18 ApoC-llA Mimetic Peptides That Antagonize ApoC-111 SG DIV 10201911974U Pending
NCI E-264-2011-0-US-11 DELIVERY OF PACKAGED RNA TO MAMMALIAN CELLS US DIV 16/709,147 Abandoned
NCI E-013-2018-0-US-02 Compositions and Methods for Treating Cancer with Anti-CD19 Immunotherapy US DIV 16/707,505 11708408 Issued PDF
NHLBI E-025-2019-0-US-01 ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF US 62/945,569 Abandoned
NCI E-085-2013-0-JP-13 Methods of Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood JP DIV 2019-221431 Issued
CC E-109-2017-0-US-03 PROGRESSIVE AND MULTI-PATH HOLISTICALLY NESTED NETWORKS FOR SEGMENTATION US National Stage 16/620,464 11195280 Issued PDF
NCI E-127-2017-0-EP-05 COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH
HPV+ MALIGNANCIES 		EP National Stage 18729515.9 Pending
NIDDK E-022-2019-0-PCT-02 A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF PCT PCT PCT/US2019/064844 Expired
NCI E-107-2017-0-US-04 T-CELLS MODIFIED TO OVEREXPRESS PHF19 US National Stage 16/619,570 11883431 Issued PDF
NCI E-175-2016-0-HK-12 ANTI-KRAS-G12D T CELL RECEPTORS HK EP 19133082.8 Issued
NCI E-495-2013-0-JP-19 Anti-Human Papillomavirus 16 E6 T Cell Receptors JP DIV 2019-219105 Issued
NHLBI E-045-2020-0-US-01 Cyclooxygenase-2 Inhibition for the Treatment of SAA-high Asthma US 62/943,087 Abandoned
NIBIB E-062-2017-0-JP-06 Systems and Methods for Three-Dimensional Fluorescence Polarization Via Multiview Imaging JP National Stage 2019-566626 Issued
NHLBI E-114-2019-0-US-02 A Pre-emphasis Technique Based On The Temperature-dependent Gradient System Behavior For Trajectory Correction In MR Imaging US ORD 16/699,415 11112472 Issued PDF
NCI E-230-2012-0-NL-76 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 NL EP 19212016.0 Issued
NCI E-230-2012-0-FR-73 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 FR EP 19212016.0 Issued
NCI E-230-2012-0-DE-74 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 DE EP 19212016.0 Issued
NCI E-230-2012-0-NO-77 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 NO EP 19212016.0 Issued
NCI E-230-2012-0-ES-78 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 ES EP 19212016.0 Issued
NCI E-230-2012-0-SE-79 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 SE EP 19212016.0 Issued
NCI E-230-2012-0-EP-17 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 EP DIV 19212016.0 Issued
NCI E-230-2012-0-BE-71 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 BE EP 19212016.0 Issued
NCI E-230-2012-0-CH-80 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 CH EP 19212016.0 Issued
NCI E-230-2012-0-GB-81 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 GB EP 19212016.0 Issued
NCI E-230-2012-0-IT-75 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 IT EP 19212016.0 Issued
NCI E-230-2012-0-DK-72 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 DK EP 19212016.0 Issued
NCI E-269-2010-0-IL-26 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE IL DIV 2021-10-27 Issued
NCI E-065-2015-0-US-07 GRIFFITHSIN MUTANTS US CON 16/697,685 11339195 Issued PDF
NCI E-127-2018-0-US-03 Compositions and Methods for Treating Cancer with Anti-CD38 Immunotherapy US ORD 16/698,186 11103533 Issued PDF
NCI E-127-2018-0-PCT-02 Compositions and Methods for Treating Cancer with Anti-CD38 Immunotherapy PCT PCT PCT/US2019/063761 Expired
NCI E-205-2010-1-US-03 PHOTOSENSITIZING ANTIBODY-FLUOROPHORE CONJUGATES US CON 16/695,674 11364298 Issued PDF
NHLBI E-149-2018-0-PCT-02 Use Of VDAC Inhibitor VBIT 4 In Lupus Treatment PCT PCT PCT/IL2019/051290 Expired
NHLBI E-149-2018-0-EP-04 Use Of VDAC Inhibitor VBIT 4 In Lupus Treatment EP National Stage 19888509.7 Abandoned
NHLBI E-149-2018-0-IL-06 Use Of VDAC Inhibitor VBIT 4 In Lupus Treatment IL National Stage 283443 Pending
NHLBI E-149-2018-0-CN-05 Use Of VDAC Inhibitor VBIT 4 In Lupus Treatment CN National Stage 201980090212.4 Pending
NCI E-044-2020-0-US-01 CODEFACS AND LIRICS PIPELINES FOR BULK EXPRESSION DECONVOLUTION US 62/940,755 Abandoned
NIAID E-103-2020-0-US-01 Improvement Of HIV-neutralizing Antibodies By Modification Of The Heavy Chain FR3 Loop And Other Regions US 62/940,572 Abandoned
NIBIB E-062-2017-0-US-07 SYSTEMS AND METHODS FOR THREE- DIMENSIONAL FLUORESCENCE POLARIZATION VIA MULTIVIEW IMAGING US National Stage 16/616,891 11428632 Issued PDF
NCI E-205-2010-2-US-20 PHOTOSENSITIZING ANTIBODY-FLUOROPHORE CONJUGATESIDS US CON 16/694,761 11364297 Issued PDF
NIAID E-042-2018-0-US-07 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING RSV G AND ITS USE US National Stage 16/616,873 11273214 Issued PDF
NIDCR E-152-2017-0-US-05 FORMATION OF STABLE CARTILAGE US National Stage 16/616,418 10940241 Issued PDF
NHLBI E-155-2016-0-US-03 LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES US CON 16/692,849 Abandoned
NCI E-151-2019-0-US-01 Optimization Of Lead Small Molecule Inhibitors Of Taspase1 For Cancer Therapeutics US 62/939,258 Abandoned
NLM E-107-2010-2-US-31 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 16/691,255 Abandoned
NLM E-107-2010-2-US-30 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 16/691,247 Abandoned